Three startups founded by Rice University graduates have won investment prizes at an annual pitch competition.

The annual H. Albert Napier Rice Launch Challenge, or NRLC, welcomed a panel of judges to hear from six alumni-founded startups in the finals last week. The prizes on the line totaled $65,000 in equity-free funding. The event, which is separate from the student version of the competition, is hosted by Rice’s Liu Idea Lab for Innovation and Entrepreneurship.

The big winner of the 2022 competition was Rhythio Medical, a preventative heart arrhythmias treatment startup. The company won first place, which included $30,000 in equity-free funding, as well as the Audience Choice Award that came with $1,500.

Taking second place, Synopic, which facilitates faster and more accurate surgical procedures through improved endoscopic vision technology, won $20,000 in equity-free funding. Lastly, Green Room, a platform that streamlines taxes and payments for touring artists, clinched third place and $15,000.

The event, named for Rice professor emeritus and entrepreneurship program founder H. Albert Napier, was sponsored by Mercury Fund, T-Minus Solutions and Chevron Technology Ventures. This year's finalists were selected by judges made up of Rice alumni. Three judges — Danielle Conkling, director at Silicon Valley Bank, Paul Manwell, senior director at Google, and Joanna Nathan, manager of new ventures at Johnson & Johnson — listened to and evaluated each company's five-minute pitch and followed up with questions.

Rhythio Medical was founded by CEO Kunal Shah, class of 2022, and Savannah Esteve, who also serves as head of product. The technology includes a surgically injected wire that makes an irregular heart work like a healthy one. It works alongside a traditional implantable cardioverter defibrillator, however, the wire but works to prevent arrhythmias, while ICDs treat arrhythmias with a painful shock to the patient’s heart. The company lists the Texas Heart Institute and the University of Texas at Austin as its research partners.